Three life science companies will IPO on Shenzhen’s Growth Enterprise Market (GEM), a new exchange that is about to launch after a long gestation period (see story). All together, ten companies were accepted as the first set of prospective listees. The exchange was established to help smaller technology companies raise money for their enterprises, with the hope that GEM will do for China what the Nasdaq market has done for the US. The three pharmaceutical companies are Lepu Medical Technology (Beijing) Co., Anhui Anke Biotechnology (Group) Co., and Chongqing Lummy Pharmaceutical Co.

AMDL Inc. (NYSE Alternext US: ADL) plans to monetize its China operations, probably by spinning off Jade Pharmaceuticals and its primary operating subsidiary, Jiangxi Bio-Chemical Pharmacy Company (JJB) (see story). AMDL hopes to finalize one or more equity private placements in JJB during the third and fourth quarters of 2009 and then list JPI/JJB, also on GEM, during the first half of 2010.

BioTime, Inc. (OTCBB: BTIM) will establish a China subsidiary, called BioTime Asia, to market the company’s stem cell products in China and throughout Asia (see story). The company will also seek to develop stem cell therapies for a number of diseases, including the use of genetically modified stem cells to treat currently incurable forms of cancer. BioTime has engaged the services of Dr. Lu Daopei, a prominent China hematologist, to manage the clinical trials of its therapeutic stem cell products.

China Biologic Products (OTCBB: CBPO), a company based on blood plasma products, entered an R&D agreement with the Institute of Blood Transfusion of Chengdu, Sichuan Province (see story). IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College. For China Biologic, the alliance will serve to strengthen its R&D capabilities and manufacturing processes.

The Mimotopes China & VPSmart-DDS Biodelivery Centers opened its doors this week in what the company hopes will become the largest supplier of research-grade peptide products in the world (see story). The Centers came into existence through the joint efforts of Mimotopes and GL Biochem (Shanghai), the largest supplier of research-grade peptide products and reagents in China. Both companies are divisions of Commonwealth Biotechnologies (NSDQ: CBTE), which is, in turn, affiliated with Venturepharm Group.

Jiangsu Yanshen Biological Technology Stock Co. was given a new drug certificate and production license from the SFDA for the company’s H1N1 flu vaccine (see story). The action brings the number of approved manufacturers of H1N1 vaccines in China to a total of six. Simcere Pharmaceutical Company (NYSE: SCR) (先声药业) owns a 37.5% stake in Jiangsu Yanshen, which it bought in May of this year for 195.5 million RMB ($28.8 million).

Hualan Biological Bacterin of Beijing has struck an H1N1 flu vaccine deal with Gulf Pharmaceutical Industries, also known as Julphar (see story). Julphar, located in Ras Al Khaimah, is the largest pharmaceutical company in the United Arab Emirates. Julphar will be the exclusive representative of Hualan’s swine flu vaccine in the Middle Ease and North Africa region (MENA).

Tianyin Pharmaceutical Co., (NYSE Amex: TPI), which produces TCM and generic pharmaceuticals, announced final results for its 2009 fiscal year, which ended June 30, 2009 (see story). The company’s revenues rose 28% to $42.9 million, while net income climbed 32% to $7.9 million. Tianyin also reiterated guidance for 2010, saying it expects revenues and net income to rise about 35% from this year.

Disclosure: none.